BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1337 related articles for article (PubMed ID: 24215736)

  • 1. Physicochemical characterization and aerosol dispersion performance of organic solution advanced spray-dried microparticulate/nanoparticulate antibiotic dry powders of tobramycin and azithromycin for pulmonary inhalation aerosol delivery.
    Li X; Vogt FG; Hayes D; Mansour HM
    Eur J Pharm Sci; 2014 Feb; 52():191-205. PubMed ID: 24215736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advanced spray-dried design, physicochemical characterization, and aerosol dispersion performance of vancomycin and clarithromycin multifunctional controlled release particles for targeted respiratory delivery as dry powder inhalation aerosols.
    Park CW; Li X; Vogt FG; Hayes D; Zwischenberger JB; Park ES; Mansour HM
    Int J Pharm; 2013 Oct; 455(1-2):374-92. PubMed ID: 23820131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, characterization, and aerosol dispersion performance modeling of advanced co-spray dried antibiotics with mannitol as respirable microparticles/nanoparticles for targeted pulmonary delivery as dry powder inhalers.
    Li X; Vogt FG; Hayes D; Mansour HM
    J Pharm Sci; 2014 Sep; 103(9):2937-2949. PubMed ID: 24740732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, characterization, and aerosol dispersion performance modeling of advanced spray-dried microparticulate/nanoparticulate mannitol powders for targeted pulmonary delivery as dry powder inhalers.
    Li X; Vogt FG; Hayes D; Mansour HM
    J Aerosol Med Pulm Drug Deliv; 2014 Apr; 27(2):81-93. PubMed ID: 24502451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, physicochemical characterization, and optimization of organic solution advanced spray-dried inhalable dipalmitoylphosphatidylcholine (DPPC) and dipalmitoylphosphatidylethanolamine poly(ethylene glycol) (DPPE-PEG) microparticles and nanoparticles for targeted respiratory nanomedicine delivery as dry powder inhalation aerosols.
    Meenach SA; Vogt FG; Anderson KW; Hilt JZ; McGarry RC; Mansour HM
    Int J Nanomedicine; 2013; 8():275-93. PubMed ID: 23355776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, characterization, and aerosolization of organic solution advanced spray-dried moxifloxacin and ofloxacin dipalmitoylphosphatidylcholine (DPPC) microparticulate/nanoparticulate powders for pulmonary inhalation aerosol delivery.
    Duan J; Vogt FG; Li X; Hayes D; Mansour HM
    Int J Nanomedicine; 2013; 8():3489-505. PubMed ID: 24092972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physicochemical characterization and aerosol dispersion performance of organic solution advanced spray-dried cyclosporine A multifunctional particles for dry powder inhalation aerosol delivery.
    Wu X; Zhang W; Hayes D; Mansour HM
    Int J Nanomedicine; 2013; 8():1269-83. PubMed ID: 23569375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physicochemical characterization and water vapor sorption of organic solution advanced spray-dried inhalable trehalose microparticles and nanoparticles for targeted dry powder pulmonary inhalation delivery.
    Li X; Mansour HM
    AAPS PharmSciTech; 2011 Dec; 12(4):1420-30. PubMed ID: 22038473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization and aerosol dispersion performance of advanced spray-dried chemotherapeutic PEGylated phospholipid particles for dry powder inhalation delivery in lung cancer.
    Meenach SA; Anderson KW; Zach Hilt J; McGarry RC; Mansour HM
    Eur J Pharm Sci; 2013 Jul; 49(4):699-711. PubMed ID: 23707466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physical Characterization of Tobramycin Inhalation Powder: I. Rational Design of a Stable Engineered-Particle Formulation for Delivery to the Lungs.
    Miller DP; Tan T; Tarara TE; Nakamura J; Malcolmson RJ; Weers JG
    Mol Pharm; 2015 Aug; 12(8):2582-93. PubMed ID: 26052676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preparation and physicochemical characterization of spray-dried and jet-milled microparticles containing bosentan hydrate for dry powder inhalation aerosols.
    Lee HJ; Kang JH; Lee HG; Kim DW; Rhee YS; Kim JY; Park ES; Park CW
    Drug Des Devel Ther; 2016; 10():4017-4030. PubMed ID: 28008226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and physicochemical characterization of advanced spray-dried tacrolimus multifunctional particles for inhalation.
    Wu X; Hayes D; Zwischenberger JB; Kuhn RJ; Mansour HM
    Drug Des Devel Ther; 2013; 7():59-72. PubMed ID: 23403805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-performing dry powder inhalers of paclitaxel DPPC/DPPG lung surfactant-mimic multifunctional particles in lung cancer: physicochemical characterization, in vitro aerosol dispersion, and cellular studies.
    Meenach SA; Anderson KW; Hilt JZ; McGarry RC; Mansour HM
    AAPS PharmSciTech; 2014 Dec; 15(6):1574-87. PubMed ID: 25139763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a novel dry powder inhalation formulation for the delivery of rivastigmine hydrogen tartrate.
    Simon A; Amaro MI; Cabral LM; Healy AM; de Sousa VP
    Int J Pharm; 2016 Mar; 501(1-2):124-38. PubMed ID: 26836711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic antibacterial effect of inhaled aztreonam and tobramycin fixed dose combination to combat multidrug-resistant Gram-negative bacteria.
    Wang J; Kutter JP; Mu H; Moodley A; Yang M
    Int J Pharm; 2020 Nov; 590():119877. PubMed ID: 32927003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advanced therapeutic inhalation aerosols of a Nrf2 activator and RhoA/Rho kinase (ROCK) inhibitor for targeted pulmonary drug delivery in pulmonary hypertension: design, characterization, aerosolization,
    Acosta MF; Muralidharan P; Grijalva CL; Abrahamson MD; Hayes D; Fineman JR; Black SM; Mansour HM
    Ther Adv Respir Dis; 2021; 15():1753466621998245. PubMed ID: 33719747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spray-dried carrier-free dry powder tobramycin formulations with improved dispersion properties.
    Pilcer G; Vanderbist F; Amighi K
    J Pharm Sci; 2009 Apr; 98(4):1463-75. PubMed ID: 18752304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dry powder inhalers of gentamicin and leucine: formulation parameters, aerosol performance and in vitro toxicity on CuFi1 cells.
    Aquino RP; Prota L; Auriemma G; Santoro A; Mencherini T; Colombo G; Russo P
    Int J Pharm; 2012 Apr; 426(1-2):100-107. PubMed ID: 22301426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formulation and characterization of lipid-coated tobramycin particles for dry powder inhalation.
    Pilcer G; Sebti T; Amighi K
    Pharm Res; 2006 May; 23(5):931-40. PubMed ID: 16715383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. L-Leucine as an excipient against moisture on in vitro aerosolization performances of highly hygroscopic spray-dried powders.
    Li L; Sun S; Parumasivam T; Denman JA; Gengenbach T; Tang P; Mao S; Chan HK
    Eur J Pharm Biopharm; 2016 May; 102():132-41. PubMed ID: 26970252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 67.